PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

No link between HIV-prevention pill Truvada and increased sexual risk behavior

Biological markers confirm behavioral data; underscore drug's effectiveness

2013-12-19
(Press-News.org) Contact information: Anne Holden
anne.holden@gladstone.ucsf.edu
415-734-2534
Gladstone Institutes
No link between HIV-prevention pill Truvada and increased sexual risk behavior Biological markers confirm behavioral data; underscore drug's effectiveness

SAN FRANCISCO, CA—December 18, 2013—In 2012 the HIV antiretroviral drug Truvada became the first and only medication approved by the FDA for HIV prevention. Led by Gladstone Institutes' Investigator Robert Grant, MD, MPH, this research was hailed as an important step towards reducing the worldwide HIV/AIDS epidemic. Now, a new study provides further proof that regular Truvada use can reduce one's risk for contracting HIV—without increasing sexual risk behavior.

This research, published today in the online journal PLOS ONE, builds on the 2010 Global iPrEx clinical study, which reported that Truvada, an FDA-approved drug used for years to treat HIV-positive patients, could also prevent new infections in people likely to come in contact with the virus. Lending further support to Truvada's efficacy, a 2012 follow-up study found that taking Truvada regularly reduced risk of HIV infection by more than 90%.

Questions about the drug's real-world effectiveness remained, however, particularly concerning the issue of whether taking the drug could lead to a behavioral effect called risk compensation. Risk compensation is the notion that individuals adjust their behavior in response to a change in their perceived level of risk—such as increasing exposure to the sun in response to sunscreen use. While iPrEx participants did self-report decreases in sexual risk behavior over the course of the study, Dr. Grant and his team decided to examine those findings more closely, by studying biological markers of risk behavior.

"After the initial iPrEx study, there was concern that self-reported behavior may not tell the whole story," said Dr. Grant, who is also a professor at the University of California, San Francisco (UCSF), with which Gladstone is affiliated. "Here, we not only gathered behavioral data, but we also tested each participant for both HIV and syphilis—allowing us to map over time how reported changes in overall behavior correlated with actual changes in infection rates."

The multi-year iPrEx study enrolled nearly 2500 men and transgender women in Peru, Ecuador, South Africa, Brazil, Thailand and the United States at risk for HIV infection. Half of the participants were given Truvada, while the other half were given a placebo. Unaware as to whether they were being given Truvada or the placebo, participants were also asked whether they believed they were receiving Truvada—and whether they thought it was working.

"If risk compensation were occurring, those who believed they were receiving Truvada and that it was effective would be more likely to increase their sexual risk behavior," explained Julia Marcus, PhD, MPH, the paper's first author. "However, our results revealed the opposite: rates of both HIV and syphilis infections went down, and there was no increase in sexual risk behavior."

"Our results suggest that HIV prevention strategies such as Truvada don't result in risk compensation because they provide an opportunity for participants to actively engage in and reduce their risk of HIV infection," added Dr. Grant. "Engagement, which also includes counseling, provision of condoms and management of other sexually transmitted infections leads to motivation, which comes at a time when motivation for preventing new HIV infections is vital to curbing the spread of this worldwide epidemic."

"The research team's findings should help to minimize reluctance to embrace Truvada over fears that it could actually lead to increased risk and more infections," said Jeffrey Crowley, distinguished scholar at the O'Neill Institute for National and Global Health Law at Georgetown University and former director of the White House Office of National AIDS Policy. "This study reinforces the importance of drugs like Truvada as one component of a comprehensive plan for supporting people living with HIV and—importantly—preventing others from becoming infected."



INFORMATION:

Dr. Marcus, who performed this research while a graduate student at the University of California, Berkeley, is now a postdoctoral fellow at the Kaiser Permanente Division of Research. Other research participants include Gladstone Senior Research Associate Vanessa MacMahan, as well as UCSF Professors David Glidden, PhD, Albert Liu MD, MPH, and Susan Buchbinder, MD. The research was funded by the US National Institutes of Health, with co-funding from the Bill and Melinda Gates Foundation.

About Truvada

Truvada is manufactured by Gilead Sciences, which donated the drug for the studies but was not otherwise involved in the research. Truvada is one tablet that contains two medications (emtricitabine and tenofovir disoproxil fumarate). The medications are available in generic forms at cost in the poorest countries of the world.

About the Gladstone Institutes

Gladstone is an independent and nonprofit biomedical-research organization dedicated to accelerating the pace of scientific discovery and innovation to prevent, treat and cure cardiovascular, viral and neurological diseases. Gladstone is affiliated with the University of California, San Francisco.



ELSE PRESS RELEASES FROM THIS DATE:

Deep brain stimulation may help with driving for people with Parkinson's disease

2013-12-19
Deep brain stimulation may help with driving for people with Parkinson's disease MINNEAPOLIS – Deep brain stimulation may have a beneficial effect on driving ability for people with Parkinson's disease, according to a new study published in the December 18, 2013, ...

Coping with stress in a changing world

2013-12-19
Coping with stress in a changing world If there is something that we all know about in the 21st century it is stress, whether it's the stress of work, financial stress or the stress of getting the next grant funded; we are all familiar with that heart-pounding, ...

Stress reaction gene linked to death, heart attacks

2013-12-19
Stress reaction gene linked to death, heart attacks DURHAM, N.C. – A genetic trait known to make some people especially sensitive to stress also appears to be responsible for a 38 percent increased risk of heart attack or death in patients with heart disease, ...

Markers of inflammation in the blood linked to aggressive behaviors

2013-12-19
Markers of inflammation in the blood linked to aggressive behaviors Finding suggests new treatments for intermittent explosive disorder, aka 'road rage' People with intermittent explosive disorder — a psychiatric illness characterized by impulsivity, ...

Newly identified immune receptor may activate B cells in autoimmunity

2013-12-19
Newly identified immune receptor may activate B cells in autoimmunity BIRMINGHAM, Ala. – A newly identified immune protein influences each person's response to vaccines and risk for autoimmune diseases like lupus and multiple sclerosis, according to a study ...

Heart disease linked with dementia in older postmenopausal women

2013-12-19
Heart disease linked with dementia in older postmenopausal women American Heart Association Rapid Access Journal Report Heart disease may put older postmenopausal women at higher risk for decreased brain function such as dementia, according to new ...

Modest weight loss may reduce heart disease, diabetes risks in middle-aged women

2013-12-19
Modest weight loss may reduce heart disease, diabetes risks in middle-aged women American Heart Association Rapid Access Journal Report Modest weight loss over 2 years in overweight or obese, middle-aged women may reduce risk factors for heart disease and diabetes, ...

Immune avoidance mechanism could lead to treatments for deadly mosquito-borne viruses

2013-12-19
Immune avoidance mechanism could lead to treatments for deadly mosquito-borne viruses PITTSBURGH, Dec. 18, 2013 – A mosquito-borne virus that kills about half of the people it infects uses a never-before-documented mechanism to ...

Neanderthal genome shows early human interbreeding, inbreeding

2013-12-19
Neanderthal genome shows early human interbreeding, inbreeding First high-quality genome sequence allows comparison with human, Denisovan DNA The most complete sequence to date of the Neanderthal genome, using DNA extracted from a woman's toe bone ...

Telecommunications data show civic dividing lines in major countries

2013-12-19
Telecommunications data show civic dividing lines in major countries New study uses network data to show communication patterns and divisions in many major nations Many residents of Britain, Italy, and Belgium imagine there to be a kind of north-south divide ...

LAST 30 PRESS RELEASES:

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

[Press-News.org] No link between HIV-prevention pill Truvada and increased sexual risk behavior
Biological markers confirm behavioral data; underscore drug's effectiveness